10 drug(s) with this reaction
50,716 total reports
Nasopharyngitis has been reported as an adverse reaction across 10 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 50,716 adverse event reports mention nasopharyngitis in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with nasopharyngitis, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have nasopharyngitis listed in their FDA adverse event reports, sorted by report count:
In addition to nasopharyngitis, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
10 drug(s) manufactured by Abbvie Inc have nasopharyngitis listed in their FDA adverse event reports: Humira, ADALIMUMAB, LEVOTHYROXINE SODIUM, UPADACITINIB, RISANKIZUMAB-RZAA, and others.
There are a combined 50,716 reports of nasopharyngitis across 10 Abbvie Inc drug(s) in the FDA adverse event database.